Choi MH, et al. - Researchers used transrectal ultrasound (TRUS) and magnetic resonance imaging (MRI) before biopsy to assess the variance in rates of detection of prostate cancer based on lesion visibility. The study sample consisted of 1,022 patients who underwent TRUS-guided prostate biopsy in 2016 and 2017. In 39.4% and 13.1% of patients with and without TRUS-visible lesions, respectively, clinically significant cancers were detected. In patients without prebiopsy MRI, the presence of TRUS-visible focal lesion increased cancer detection rate. Findings suggested a significant association of TRUS- and MRI-visible focal lesions in the prostate with the detection of clinically significant cancer.